VBI Vaccines Company Overview
About VBI Vaccines
VBI Vaccines (NASDAQ:VBIV) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative vaccines for the prevention and treatment of infectious diseases and cancer. Their portfolio includes Sci-B-Vac®, a commercial third-generation hepatitis B vaccine, and an enveloped virus-like particle (eVLP) platform through which they develop vaccine candidates targeting cytomegalovirus (CMV), coronavirus (COVID-19), and other infectious diseases. VBI reflecting its commitment to advancing public health across global markets. The company aims to address some of the world's most pressing healthcare challenges by leveraging its expertise in vaccine research and development to bring new solutions to patients worldwide.
Snapshot
Operations
Produtos e/ou serviços de VBI Vaccines
- PreHevbrio, a 3-antigen hepatitis B vaccine for adults.
- Sci-B-Vac, a commercial-stage hepatitis B vaccine offered in Israel and 10 other countries.
- VBI-1901, a therapeutic vaccine candidate for glioblastoma.
- VBI-1501, a prophylactic vaccine candidate for cytomegalovirus (CMV).
- Pan-COVID-19 vaccine candidates, designed to provide broader protection against various coronavirus strains.
equipe executiva do VBI Vaccines
- Mr. Jeffery R. Baxter FCMAPresident, CEO & Director
- Ms. Nell BeattieCFO, Head of Corporate Development & Director
- Dr. David Evander Anderson Ph.D.Chief Scientific Officer
- Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D.Chief Medical Officer
- Ms. Nicole AndersonDirector of Corporate Communications & Investor Relations
- Ms. Athena KartsaklisSenior VP of Finance, Chief Compliance Officer & Principal Financial Officer
- Mr. Avi MazaltovGlobal Head of Manufacturing & GM of SciVac
- Mr. Misha NossovSenior VP of Global Commercial Supply Strategy & Head of Europe
- Mr. T. Adam Buckley B.Sc., MBASenior Vice President of Business Development
- Mr. John Robert DillmanChief Commercial Officer